HER-2/neu (c-erb-B2) gene and protein in breast cancer

American Journal of Clinical Pathology

Volumn 112, Issue 1 SUPPL. 1, 1999, Pages

  Ross, Jeffrey S ^a   Fletcher, Jonathan A ^a  

^a NONE

Author keywords

Breast neoplasms; HER 2 neu; Prognosis; Proto oncogene c erb B2; Therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DNA; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; METHOTREXATE; ONCOPROTEIN; PACLITAXEL; RECEPTOR PROTEIN; TAMOXIFEN; TENIPOSIDE; TRASTUZUMAB; TYROSINE KINASE RECEPTOR;

BREAST CANCER; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; ENZYME IMMUNOASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SOUTHERN BLOTTING;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; GENE EXPRESSION; GENES, ERBB-2; GENETIC TECHNIQUES; HUMANS; MALE; RECEPTOR, ERBB-2;

EID: 0033500183     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (149)

1. Lupu R, Cardillo M, Harris L, et al. Interaction between ERB-receptors and heregulin in breast cancer tumor progression and drug resistance. Semin Cancer Biol. 1995;6:135-145.
2. Slamon DJ, Clark GM. Amplification of C-erb-B2 and aggressive breast tumors? Science. 1988;240:1795-1798.
3. De Potter CR. The neu oncogene: more than a prognostic indicator? Hum Pathol. 1994;25:1264-1268.
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
5. Berger MS, Locher GW, Saurer S, et al. Correlation of c-erb-b2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988;48:1238-1243.
6. van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. N Engl J Med. 1988;319:1239-1245.
7. Heintz NH, Leslie KO, Rogers LA, et al. Amplification of the c-erb B-2 oncogene in prognosis of breast adenocarcinoma. Arch Pathol Lab Med. 1990;114:160-163.
8. Wright C, Angus B, Nicholson S, et al. Expression of c-erb B-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087-2090.
9. Tsuda H, Hirohashi S, Shimosato Y et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma: a retrospective analysis of 176 cases. Cancer. 1990;65:1794-1800.
10. Borg A, Tandon AK, Sigurdsson H, et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res. 1990;50:4332-4337.
11. Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the Nations Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erb B2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103-112.
12. Battifora H, Gaffey M, Esteban J, et al. Immunohistochemical assay of neu/c-erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol. 1991;4:466-474.
13. Kallioniemi OP, Holli K, Visakorpi T, et al. Association of C-erb B2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer. 1991;49:650-655.
14. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer. 1991;63:434-438.
15. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res. 1991; 51:944-948.
16. Lovekin C, Ellis IO, Locker A, et al. C-erb B2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991;63:439-443.
17. McCann AH, DeDervan TA, O'Regan M, et al. Prognostic significance of C-erb B2 and estrogen receptor status in human breast cancer. Cancer Res. 1991;51:3296-3303.
18. Dykens R, Corbett IP, Henry J, et al. Long term survival in breast cancer related to overexpression of the C-erb B2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol. 1991;163:105-110.
19. Rilke F, Colnaghi MI, Cascinelli N, et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49:44-49.
20. Winstanley J, Cooke T, Murray GD, et al. The long term prognostic significance of C-erb B2 in primary breast cancer. Br J Cancer. 1991;63:447-450.
21. O'Reilly SM, Barnes DM, Camplejohn RS, et al. The relationship between C-erb B2 expression, and s-phase fraction in prognosis of breast cancer. Br J Cancer. 1991;63:444-446.
22. Paterson MC, Dietrich KD, Danyluk J, et al. Correlation between C-erb B2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res. 1991;51:556-567.
23. Toikkanen S, Helin H, Isola J, et al. Prognostic significance of Her-2 oncoprotein expression in breast cancer: a 30-year follow up. J Clin Oncol. 1992;10:1044-1048.
24. Molina R, Ciocca DR, Candon AK, et al. Expression of HER-2/neu oncoprotein in breast cancer: a comparison of immunohistochemical and Western blot techniques. Anticancer Res. 1992;12:1965-1991.
25. Noguchi M, Koyasaki M, Ohta N, et al. c-erb B-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer. 1992;69:2953-2960.
26. Allred DC, Clark GM, Tandon AK, et al. HER-2/neu node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in-situ carcinoma. J Clin Oncol. 1992;10:599-605.
27. Babiak J, Hugh J, Poppeme S. Significance of c-erb B-2 amplification in DNA aneuploidy: analysis in 78 patients with node-negative breast cancer. Cancer. 1992;70:770-776.
28. Tiwari RK, Borgen PI, Wong GY, et al. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res. 1992;12:419-426.
29. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of C-erb B2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
30. Bianchi S, Paglierani M, Zampi G, et al. Prognostic significance of C-erb B2 expression in node negative breast cancer. Br J Cancer. 1993;67:625-629.
31. Press MF, Pike MC, Chazin VR, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantification by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993;53:4960-4970.
32. Seshadri R, Firgaira FA, Horsfall DJ, et al. Clinical significance of Her-2/neu oncogene amplification in primary breast cancer. J Clin Oncol. 1993;11:1936-1942.
33. Descotes F, Pavy JJ, Adessi GL. Human breast cancer: correlation study between Her-2/neu amplification and prognostic factors in an unselected population. Anticancer Res. 1993;13:119-124.
34. Giai M, Roagna R, Ponzone R, et al. Prognostic and predictive relevance of C-erb B2 and ras expression in node positive and negative breast cancer. Anticancer Res. 1994;14:1441-1450.
35. Muss HB, Thor AD, Berry DA, et al. C erb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-1266.
36. Tetu B, Brisson J. Prognostic significance of Her-2/neu oncogene expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer. 1994;73:2359-2365.
37. Hartmann LC, Ingle JN, Wold LE, et al. Prognostic value of C erbBZ overexpression in axillary lymph node positive breast cancer: results from a randomized adjuvant treatment protocol. Cancer. 1994;74:2956-2963.
38. Jacquemeier J, Penault-Llorca P, Viens P, et al. Breast cancer response to adjuvant chemotherapy in correlation with erb B2 and p53 expression. Anticancer Res. 1994;4:2773-2778.
39. Marks JR, Humphrey PA, Wu K, at al. Overexpression of p53 and Her-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg. 1994;219:332-341.
40. Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of Her-2/neu expression in patients with axillary lymph node-negative breast carcinoma: a study of epidemiologic risk factors, histologic features and prognosis. Cancer. 1995;75:1320-1326.
41. Quenel N, Wafflart J, Bonichon F, et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat. 1995;35:283-291.
42. Sundblad AS, Pellicer EM, Ricci L. Carcinoembryonic expression in stages I and II breast cancer: its relationship with clinicopathologic factors. Hum Pathol. 1996;27;297-300.
43. O'Malley FP, Saad Z, Kerkvliet N, et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and C-erb B2 in lymph node-negative breast cancer. Hum Pathol. 1996;27:955-963.
44. Hieken TJ, Mehta RR, Shilkaitis A, et al. Her-2/neu and p53 expression in breast cancer: valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry. Proc Annu Meet Am Soc Clin Oncol. 1996;15. Abstract 113.
45. Xing WR, Gilchrist KW, Harris CP, et al. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat. 1996;39:203-212.
46. Dittadi R, Brazzale A, Pappagallo G, et al. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res. 1997;17:1245-1247.
47. Fernandez-Acenero MJ, Farina Gonzalez J, Arangoncillo Ballesteros P. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis. Gen Diagn Pathol. 1997;142:289-296.
48. Eissa S, Khalifa A, el-Gharib A, et al. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res. 1997;17:3091-3097.
49. Charpin C, Garcia S, Bouvier C, et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer. 1997;75:1667-1673.
50. Press MJ, Bernstein L, Thomas PA, et al. Her-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997;15:2894-2904.
51. Ross JS, Muraca PJ, Jaffe D, et al. Multivariate analysis of prognostic factors in lymph node negative breast cancer [abstract]. Mod Pathol. 1998;11:26.
52. cdc2 cyclin dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in-situ hybridization in breast cancer [abstract]. Mod Pathol. 1998;11:18.
53. Querzoli P, Albonico G, Ferretti S, et al. Modulation of biomarkers in minimal breast carcinoma. Cancer. 1998;83:89-97.
54. Andrulis IL, Bull SB, Blasckstein MA, et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol. 1998;6:1340-1349.
55. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462-469.
56. Page DL. Prognosis and breast cancer: recognition of lethal and favorable prognostic types. Am J Surg Pathol. 1991;15:334-349.
57. Porter-Jordan K, Lippman ME. Overview of the biologic markers in breast cancer. Hematol Oncol Clin North Am. 1994;8:73-100.
58. McGuire WL, Tandon AK, Allred DC, et al. How to use prognostic factors in axillary node-negative breast cancer patients. J Natl Cancer Inst. 1990;82:1006-1015.
59. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
60. Sauter G, Feichter G, Torhorst J, et al. Fluorescence in-situ hybridization for detecting ERBB-2 amplification in breast tumor fine needle aspiration biopsies. Acta Cytol. 1996;40:164-173.
61. Allred DC, Harvey JM, Berardo M, et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11:155-168.
62. Kallioemi OP, Kallionemi A, Kurisu W, et al. ERBB2 in breast cancer alanyzed by fluoresecence in situ hybridization. Proc Natl Acad Sci. 1992;89:5321-5325.
63. Persons DL, Borelli KA, Hsu PH. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol. 1997;10:720-727.
64. Gerdes AM, Nielson O, Mohr U, et al. Correlation between molecular genetic analyses and immunohistochemical evaluation of the epidermal growth factor receptor and p185HER2. Anticancer Res. 1998;18:2529-2534.
65. Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 1996;88:1054-1059.
66. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol. 1998;51:370-374.
67. Penault-Llorca F, Adelaide J, Houvenaeghel G, et al. Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation. J Pathol. 1994;173:65-75.
68. Busmanis I, Feleppa F, Jones A, et al. Analysis of C-erb B2 expression using a panel of six commercially available antibodies. Pathology. 1994;26:261-267.
69. Press MF, Hung G, Godolphin W, et al. Sensitivity of Her-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res. 1994;54:2771-2777.
70. Keshgegian AA, Cnaan A. erbB2 oncoprotein expression in breast carcinoma: poor prognosis associated with high degree of cytoplasmic positivity using CB-11 antibody. Am J Clin Pathol. 1997;108:456-463.
71. Taylor SL, Platt-Higgins A, Rudland PS, et al. Cytoplasmic staining of c-erbB-2 is not associated with the presence of detectable c-erbB-2 mRNA in breast cancer specimens. Int J Cancer. 1998;76:459-463.
72. vanDiest PJ, vanDam P, Henzen-Logmans SC, et al. A scoring system for immunohistochemical staining: consensus report of the Task Force for Basic Research of the EORTC-GCGC. J Clin Pathol. 1997;50:801-804.
73. Valeron PF, Chirino R, Vega V, et al. Quantitative analysis of p185(HER-2/neu) protein in breast cancer and its association with other prognostic factors. Int J Cancer. 1997;74:175-179.
74. Koscielny S, Terrier P, Daver A, et al. Quantitative determination of c-erbB-2 in human breast tumours: potential prognostic significance of low values. Eur J Cancer. 1998;34:47-481.
75. Ross JS, Sheehan C, Hayner-Buchan A, et al. HER-2/neu gene amplification status in prostate cancer by fluorescence in-situ hybridization. Hum Pathol. 1997;28:827-833.
76. Lodato RF, Maguire HC, Greene MI, et al. Immunohistochemical evaluation of cerb B2 oncogene expression in ductal carcinoma in-situ and atypical ductal hyperplasia of the breast. Mod Pathol. 1990;3:449-454.
77. Allred DC, Clark GM, Molina R, et al. Overexpression of Her-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer. Hum Pathol. 1992;23:974-979.
78. Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in-situ carcinoma of the breast analyzed with a new classification. Semin Diagn Pathol. 1994;11:208-214.
79. Brower FT, Ahmed S, Tartter P, et al. Prognostic variables in invasive breast cancer: contribution of comedo versus non-comedo in-situ component. Ann Surg Oncol. 1995;2:440-444.
80. Leal CB, Schmitt FC, Bento NJ, et al. Ductal carcinoma insitu of the breast: histologic categorization and its relationship to ploidy and immunohistochemical expression of hormone receptors, p53 and C erb B-2 protein. Cancer. 1995;75:2123-2131.
81. Bobrow WLG, Happerfield LC, Gregory WM, et al. Ductal carcinoma in-situ: assessment of necrosis in nuclear morphology and their association with biological markers. J Pathol. 1995;176:333-341.
82. De Potter CR, Schelhout AM, Verbeeck P, et al. Neu overexpression correlates with extent of disease in large cell ductal in situ carcinoma of the breast. Hum Pathol. 1995;26:601-606.
83. Inaji H, Koyama H, Motomura K, et al. Differential distribution of erb B2 and pS2 proteins in ductal carcinoma in-situ of the breast. Breast Cancer Res Treat. 1996;37:89-92.
84. Albonico G, Querzoli P, Ferretti S, et al. Biophenotypes of breast carcinoma in-situ defined by image analysis of biological parameters. Pathol Res Pract. 1996;192:117-123.
85. Bose S, Lesser ML, Norton L, et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med. 1996;120:81-85.
86. Moreno A, Lloveras B, Figueras A, et al. Ductal carcinoma insitu of the breast: correlation between histologic classification and biologic markers. Mod Pathol. 1997;10:1088-1092.
87. Mack L, Kerkzelit N, Doig G, et al. Relationship of a new histological categorization of ductal carcinoma in-situ of the breast with size and the immunohistochemical expression of p53, C-erb B2, bcl2 and ki-67. Hum Pathol. 1997;28:974-979.
88. Porter PL, Garcia R, Moe R, et al. cerb B2 oncogene protein in in-situ and invasive lobular breast neoplasia. Cancer. 1991;68:331-334.
89. Rosenthal SI, Depowski PL, Sheehan CE, et al. HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular breast cancer [abstract]. Mod Pathol. 1999;12:29.
90. Wolber RA, DuPuis BA, Wick MR. Expression of cerb B2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol. 1991;96:243-247.
91. Lilleng R, Hagmar BM, Nesland JM. cerb B2 protein and neuroendocrine expression in intraductal carcinomas of the breast. Mod Pathol. 1992;5:41-47.
92. Yeh IT, Keykhah S, Selig AM, et al. Expression of erb B2 gene in the benign and proliferative breast tissue. Surg Pathol. 1993;5:109-120.
93. Hanna W, Kahn HJ, Andrulis I, et al. Distribution and patterns of staining of neu oncogene product in benign and malignant breast diseases. Mod Pathol. 1990;3:455-461.
94. Odagiri E, Kanda N, Jibiki K, et al. Reduction of Telomeric-linked cerb B2 gene amplification in human breast cancer, fibroadenoma, and gynecomastia: relationship to histologic grade and clinical parameters. Cancer. 1994;73:2978-2984.
95. Gattuso P, Reddy VB, Green LK, et al. Prognostic factors for carcinoma of the male breast. Int J Surg Pathol. 1995;2:199-206.
96. Joshi MG, Lee AK, Loda M, et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer. 1996;77:490-498.
97. Willsher PC, Leach IH, Ellis IO. Male breast cancer: pathological and immunohistochemical features. Anticancer Res. 1997;17:2335-2338.
98. Bines J, Goss B, Hussong J, et al. C-erb and p53 overexpression as predictors of survival in patients with male breast cancer. Proc Annu Assoc Clin Oncol. 1997;16. Abstract 558.
99. Bruce DM, Heyes SD, Payne S, et al. Male breast cancer: clinico-pathological features, immunocytochemical characteristics and prognosis. Eur J Surg Oncol. 1996;22:42-46.
100. Dawson PJ, Paine TM, Wolman SR. Immunocytochemical characterization of male breast cancer. Mod Pathol. 1992;5:621-625.
101. Wright C, Nicholson S, Angus B, et al. Relationship between C-ERBB 2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118-121.
102. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum C-erb B2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 1995;13:1129-1135.
103. Berns EM, Foekens JA, vanStaveren IL, et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene. 1995;159:11-18.
104. Stahl O, Sullivan S, Wingren S, et al. C-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer (abstract). Eur J Cancer. 1995;31A:2185-2190.
105. Archer SG, Eliopoulis SA, Spandidos D, et al. Expression of ras, p21, p53 and C-erb B2 in advanced breast cancer and response to line hormonal therapy. Br J Cancer. 1995;72:1259-1266.
106. Yu D, Liu B, Tan M, et al. Overexpression of cerbB2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene. 1996;13:1359-1365.
107. Carlomagno C, Perrone F, Gallo C, et al. CerbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol. 1996;14:2702-2708.
108. Haffty BG, Brown F, Carter D, et al. Evaluation of HER-2/neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int J Radiat Oncol Biol Phys. 1996;35:751-757.
109. Revillion F, Hebbar M, Boneterre J, et al. Plasma CerbB2 concentrations in relation to chemotherapy in breast cancer patients. Eur J Cancer. 1996;32a:231-234.
110. Baselga J, Seidman AD, Rosen PP, et al. HER-2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology. 1997;11:43-48.
111. Pegram MD, Finn RS, Arzoo K, et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene. 1997;15:537-547.
112. Newby JC, Johnston SRD, Smith IE, et al. Expression of epidermal growth factor receptor and C-erb B2 during the development of tamoxifen resistance in human breast cancer. Clin Cancer Res. 1997;3:1643-1651.
113. Burke HB, Hoang A, Iglehart JD, et al. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer. 1998;82:874-877.
114. Yamaguchi H, O'Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 1997;15:2518-2525.
115. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res. 1998;4:7-12.
116. Yu D, Liu B, Jing T, et al. Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. Oncogene. 1998;16:2087-2094.
117. Bianco AR, De Laurentiis M, Carlomagno C, et al. 20 year update of the Naples Gun trial of adjuvant breast cancer therapy: evidence of interaction between c-erb-B2 expression and tamoxifen efficacy. In: Proceedings of the American Society of Clinical Oncology. 1998;17:97. Abstract.
118. Ravdin PM, Green S, Albain V, et al. Initial report of the SWOG biological correlative study of C-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone. In: Proceedings of the American Society of Clinical Oncology. 1998;17:97. Abstract.
119. Jarvinen TA, Holli K, Kuukasjarvi T, et al. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemo-therapy in advanced breast cancer. Br J Cancer. 1998;77:2267-2273.
120. Isola JJ, Holli K, Oksa H, et al. Elevated erb B-2 oncoprotein levels in preoperative and follow-up serum samples defined in aggressive course in patients with breast cancer. Cancer. 1994;73:652-658.
121. Kandl H, Seymour L, Bezwoda WR. Soluable c-erb B-2 fragments in serum correlates with disease stage and predicts more shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer. 1994;70:739-742.
122. Wu JT, Astill ME, Gagon SD, et al. Measurement of C-erb B2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: correlation with serum tumor markers and membrane-bound oncoproteins. J Clin Lab Anal. 1995;9:151-165.
123. Andersen TI, Paus E, Nesland JM, et al. Detection of C-erb B2 related proteins in sera from breast cancer patients: relationship to ERBB2 gene amplification and Cerb B2 protein overexpression in tumour. Acta Oncol. 1995;34:499-504.
124. Volas GH, Leitzel K, Teramoto Y, et al. Serial serum C-erbB-2 levels in patients with breast carcinoma. Cancer. 1996;78:267-272.
125. Molina R, Jo J, Vanon G, et al. Utility of cerbB2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA15.3. Br J Cancer. 1996;74:1126-1131.
126. Willsher PC, Beaver J, Pinder S, et al. Prognostic significance of serum CerbB2 protein in breast cancer patients. Breast Cancer Res Treat. 1996;40:251-255.
127. Fehm T, Maimonis P, Wetz S, et al. Influence of circulating C-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat. 1997;43:87-95.
128. Mansour OA, Zekri AR, Harvey J, et al. Tissue in serum CerbB2 and tissue EGFR in breast carcinoma: three years follow-up. Anticancer Res. 1997;17:3101-3106.
129. Disis ML, Pupa SM, Gralow JR, et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol. 1997;15:3363-3367.
130. Krainer M, Brodowicz T, Zeillinger R, et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology. 1997;54:475-481.
131. Fehm T, Maimonis P, Katalinic A, et al. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology. 1998;55:33-38.
132. Mehta RR, McDermott JH, Hieken TJ, et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol. 1998;16:2409-2416.
133. Shepard HM, Lewis GD, Sarup JC, et al. Monoclonal antibody therapy of human cancer: taking the Her-2 protooncogene to the clinic. J Clin Immunol. 1991;11:117-127.
134. Zhang L, Chang C, Bacus SS, et al. Suppressed transformation and induced differentiation of Her-2/neu-overexpressing breast cancer cells by emodin. Cancer Res. 1995;55:3890-3896.
135. Jinno H, Ueda M, Enomoto K, et al. Effectiveness of an Adriamycin immunoconjugate that recognizes the CerbB2 product on breast cancer cell lines. Surg Today. 1996;26:501-507.
136. Liu X, Pogo BG. Inhibition of erbB2 positive breast cancer cell growth by erbB2 antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1996;6:9-16.
137. Wright M, Grim J, Deshane J, et al. An intracellular anti-erbB-2 single-chain antibody is specifically cytotoxic to human breast carcinoma cells overexpressing erbB-2. Gene Ther. 1997;4:317-322.
138. Heijnen IA, Buhring HJ, Deo YN, et al. The clinical studies with Fc(Gamma)R by specific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpression in breast cancer. Cancer Res. 1997;57:696-701.
139. Witters LM, Kumar R, Chinchilli ZM, et al. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat. 1997;42:1-5.
140. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 (Herceptin™) enhances the amitumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts. Cancer Res. 1998;58:2825-2831.
141. Gu XG, Schmitt M, Hiasa A, et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vtiro and in vivo cellular and humeral immune response against HERZ-expressing murine sarcomas. Cancer Res. 1998;58:3385-3390.
142. Roh H, Pippin J, Boswell C, et al. Antisense oligonucleotides specific for the HER2/neu oncogene inhibit the growth of human breast carcinoma cells that overexpress HER2/neu. J Surg Res. 1998;77:85-90.
143. Valone FH, Kaufman PA, Guyre PM, et al. Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the protooncogene HER-2/neu. J Clin Oncol. 1995;13:2281-2292.
144. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti p185 Her-2 monoclonal antibody in patients with Her-2/neu overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737-744.
145. R (humanized anti-human HER-2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer. In: Proceedings of the American Society of Clinical Oncology. 1998;17:97. Abstract.
146. R (humanized anti HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. In: Proceedings of the American Society of Clinical Oncology. 1998;17:98. Abstract.
147. Brossart P, Stuhler J, Flad P, et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. 1998;58:732-736.
148. Disis ML, Grabstein KH, Cheaver MA. HER-2/neu peptide vaccines ellicit T cell immunity to the HER-2/neu protein in patients with breast and ovarian cancer. In: Proceedings of the American Society of Clinical Oncology. 1998;17:97. Abstract.
149. Allan SM, Dean CJ, Eccles S, et al. Clinicoradioimmunolocalization with a rat monoclonal antibody directed against C-erb B2. Cell Biophys. 1994;24:93-98.